While the potential for therapeutic cancer vaccines has been recognized, based on modest clinical trials in the metastatic setting, a gap exists between the limited clinical activity of cancer vaccines and promising preclinical findings. Morseet al. discuss the relevance of appropriate platforms for cancer vaccine testing, identification of the most important biologic endpoints, and reiterate the need to improve our understanding of how to manipulate the immune system beyond the initial vaccine-induced stimulation. The authors focus on the areas of cancer vaccine development that will translate into clinical application.
- Michael A Morse
- Stephen Chui
- Timothy Clay
